Van-Loc Nguyen

The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.

Christophe Simon, P. Bamborough, R. Prinjha, 2014, Journal of medicinal chemistry.

Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors.

F. Gellibert, G. Krysa, S. Huet, 2009, Bioorganic & medicinal chemistry letters.

Discovery and Optimization of Potent, Selective, and in Vivo Efficacious 2-Aryl Benzimidazole BCATm Inhibitors.

C. Chung, E. Nicodème, C. Arico-Muendel, 2016, ACS medicinal chemistry letters.

From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.

E. Nicodème, J. Kirilovsky, L. Trottet, 2012, Bioorganic & medicinal chemistry letters.

Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.

M. Lambert, H. Xu, D. Grillot, 2007, Journal of medicinal chemistry.

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

David W. Gray, A. Hill, G. Drewes, 2018, Journal of medicinal chemistry.

Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.

Françoise Gellibert, James M. Woolven, C. Janson, 2004, Journal of medicinal chemistry.

Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.

James M. Woolven, N. Laping, F. Gellibert, 2006, Journal of medicinal chemistry.